Skip to content Skip to footer
New Drug Designations - December 2024

New Drug Designations – December 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, EMA, MHLW and NMPA   The December 2024 report covers designations granted to 43 drugs and 3 devices, encompassing 13 small molecules, 10 biologics, 7 cell and gene therapies & 3 medical devices among others  Significant…

Read more

Know Your Investor RA Capital Management (January’25 Edition)

Know Your Investor: RA Capital Management (January’25 Edition)

Shots:    The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences  In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding  Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…

Read more

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots: In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…

Read more

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:   In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…

Read more

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots: The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024 Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…

Read more

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

J.P. Morgan Healthcare Conference Special: Dealmaker of the Year 2024 (Part 01)

Shots:  The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024  Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion   Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…

Read more

Animal Health Top 20 2024

Top 20 Animal Health Companies of 2024

Shots: The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental care The global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030 PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of…

Read more

Know Your Investor- Surveyor Capital (December’24 Edition) 

Know Your Investor: Surveyor Capital (December’24 Edition) 

Shots:   A longstanding equities business within Citadel, Surveyor Capital invests in the consumer, financials, healthcare, industrials, and Technology, Media & Telecom sectors  In 2023, Surveyor participated in four funding rounds, investing approximately $2.35B and adding 17 companies to its portfolio  For a curated report on a specific investor or venture capital firm, reach out to…

Read more